1. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-14 discussion 14-5. PMID:
17049716
2. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36. PMID:
12811491
4. Schena G, Caplan MJ. Everything you always wanted to know about β(3)-AR * (* but were afraid to ask). Cells 2019;8:357.
5. Yamaguchi O. Beta3-adrenoceptors in human detrusor muscle. Urology 2002;59:25-9.
6. Gormley EA, Lightner DJ, Faraday M, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 2015;193:1572-80. PMID:
25623739
7. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU guidelines on the assessment of nonneurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2015;67:1099-109. PMID:
25613154
8. Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Vibegron, a novel potent and selective β(3)-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol 2018;73:783-90. PMID:
29366513
10. Barry MJ, Williford WO, Chang Y, Machi M, Jones KM, Walker-Corkery E, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995;154:1770-4. PMID:
7563343
11. Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res 2008;20 Suppl 3:S11-8.
13. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996;335:533-9. PMID:
8684407
14. Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et al. EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO) 2020. European Association of Urology Guidelines. 2020 Edition. Arnhem (The Netherlands): European Association of Urology Guidelines Office; 2020.
18. Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am 2016;43:289-97. PMID:
27476122
19. Kakizaki H, Lee KS, Yamamoto O, Jong JJ, Katou D, Sumarsono B, et al. Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH). Eur Urol Focus 2020;6:729-37. PMID:
31718957
21. Matsukawa Y, Gotoh M. Factors contributing to the efficacy of two add-on therapies of fesoterodine or mirabegron to silodosin monotherapy for persistent overactive bladder in men with lower urinary tract symptoms. Int J Urol 2020;27:85-6. PMID:
31538373
22. Nitti V, Rosenberg S, Mitcheson HD, He W, Fakhoury A, Martin N. 1869 Randomized, multicenter phase II study evaluating the urodynamic safety of mirabegron in males with lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO). J Urol 2012;187:e756.
23. Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189:1388-95. PMID:
23079373
24. Ichihara K, Masumori N, Fukuta F, Tsukamoto T, Iwasawa A, Tanaka Y. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol 2015;193:921-6. PMID:
25254938
25. Kaplan SA, Herschorn S, McVary KT, Staskin D, Chapple C, Foley S, et al. Efficacy and safety of mirabegron versus placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a randomized, phase 4 study (PLUS). J Urol 2020;203:1163-71. PMID:
31895002
26. Matsukawa Y, Takai S, Majima T, Funahashi Y, Sassa N, Kato M, et al. Comparison in the efficacy of fesoterodine or mirabegron addon therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: a randomized, prospective trial using urodynamic studies. Neurourol Urodyn 2019;38:941-9. PMID:
30779375
29. Nitti VW, Rosenberg S, Mitcheson DH, He W, Fakhoury A, Martin NE. Urodynamics and safety of the β3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol 2013;190:1320-7. PMID:
23727415
30. Ogura K, Sengiku A, Miyazaki Y, Sawazaki H, Takahashi T. 1091 Effects of add-on mirabegron on storage symptoms in men with lower urinary tract symptoms receiving alpha-1 blocker therapy. Eur Urol Suppl 2013;12:e1091.